News

East River BioSolutions moved to a new location at the SUNY Downstate Advanced Biotechnology Incubator

July 1, 2018

Brooklyn, New York

We are pleased to announce that East River BioSolutions has expanded and moved to a new location at the SUNY Downstate Advanced Biotechnology Incubator in Brooklyn, New York. Our new address is 760 Parkside Avenue, Brooklyn, New York 11226.

Since 2016, the Alexandria Center for Life Science, and especially Alexandria LaunchLabs, provided East River Bio a home –  a central location, interactive life science campus, shared resources, access to new customers and partners, and an outstanding community of scientists and entrepreneurs. As our sales and team continued to grow, we were in need of a larger space to accommodate our team and a significantly expanded production facility.

Our expansion into Brooklyn represents an exciting new chapter in East River Bio’s story, and we look forward to continued successes as we scale and diversify our R&D and production efforts. Feel free to stop by and say ‘hi’ if you’re in the area!

Team updates

We would like to congratulate our Chair of the Board, Gordana Vunjak-Novakovic, for her appointment to the rank of University Professor, Columbia’s highest academic honor!

Read full story here.

MatriTek becomes East River BioSolutions

On April 25th 2017, MatriTek revealed its new name: East River BioSolutions.

The broader, more encompassing name better captures the company’s vision of revolutionizing the biomedical research and regenerative medicine markets.

“We have an exceptional track record of engineering and scientific excellence and are at the forefront of unlocking the power of native tissue matrix to develop innovative solutions to serve the life sciences industry. Going forward as East River BioSolutions, we will leverage that expertise to provide a wider range of cutting edge products,” commented Andrea Nye, CEO of East River BioSolutions.

East River BioSolutions will continue to strengthen its leading portfolio of tissue-specific extracellular matrices, complementing it with new offerings such as tissue-specific bio-inks and expanding application of its technologies in the growing therapeutic and biomedical markets.